Novo Nordisk is dedicated to supporting your patients.

Explore our services, tools, and resources. Or, connect with a Novo Nordisk representative to learn more.

Sion, walking with backpack.

Sion, walking with backpack.

Sion lives with hemophilia A.

QuickCheck™.

QuickCheck™ offers benefits verification. A NovoSecure™ Specialist assists to verify coverage, and usually within 4 hours, your office will receive the Summary of Benefits.

Get the Details

Product support.

Novosecure™ website home page

Novo Nordisk offers services through NovoSecure™, a support program designed to assist your qualifying patients throughout the reimbursement process.

Patient education.

Novoeight® brochure

Our informative educational resources can help your patients learn more about living with hemophilia. Download, share, or order for your office.

View Educational Materials

Patient stories.

Team Novo8™ is a group of patients who switched to Novoeight^® and spend their time helping others with hemophilia A. Hear more about their mission, and how your patients can benefit from their experiences.

Meet Team Novo8™

Five standing human silhouettes

Have a question? We’re here to help.

Enter your zip code to search for a Novo Nordisk representative.

Available from Novo Nordisk:

Visit website | Prescribing Information

Visit website | Prescribing Information

Visit website | Prescribing Information

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight^® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight^® and administer appropriate treatment.

Indications and Usage

Novoeight^® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight^® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight^® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight^® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.